NASDAQ$DH

Definitive Healthcare Corp · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Definitive Healthcare's financial performance for Q3 2023 increased, with revenue growing and adjusted EBITDA profitability improving.

Definitive Healthcare reported a 14% year-over-year increase in revenue, reaching $65.3 million for Q3 2023. The company's adjusted EBITDA was $21.7 million, representing 33% of revenue, compared to $16.4 million in Q3 2022.

  • Revenue increased by 14% year-over-year to $65.3 million.
  • Net loss was ($248.7) million, or 381% of revenue.
  • Adjusted Net Income increased to $14.6 million, compared to $8.8 million in Q3 2022.
  • Adjusted EBITDA was $21.7 million, or 33% of revenue, compared to $16.4 million, or 29% of revenue in Q3 2022.

Headline financials

Total Revenue

$65.3M

Previous: $57.4M+13.8%
EPS (adj)

$0.09

Previous: $0.06+50.0%
Adjusted Net Income

$14.6M

No prior period
Cash Flow from Operations

$9.5M

Previous: $10.7M-11.2%
Unlevered Free Cash Flow

$17.7M

No prior period
Capital Expenditures

-$2.38M

Previous: $1.88M-226.9%
Free Cash Flow

-$174M

Previous: -$2.69M-6367.4%
Net Income

-$172M

Previous: -$2.69M-6278.8%
Operating Income

-$295M

Previous: -$9.43M-3032.0%
Gross Profit

$53.4M

Previous: $47.7M+12.1%
Cash & Equivalents

$77.5M

Previous: $229M-66.1%
Total Assets

$1.82B

Previous: $2.12B-14.2%
R&D Expense

$10.8M

No prior period
Stock-Based Comp

$12M

Previous: $9.13M+31.3%

Revenue & EPS history

Definitive Healthcare · Revenue · Quarterly

$65.3M

Q3 2023+13.8%vs Q3 2022
Beat estimate in 12 of 14 quarters(86%)
ActualEstimate

Forward guidance

The Company is issuing the following financial guidance for Fourth Quarter 2023:

Tailwinds

  • Revenue is expected to be in the range of $65.5 – $66.5 million, an 8-10% increase year over year.
  • Adjusted Operating Income is expected to be in the range of $17.5 – $18.5 million.
  • Adjusted EBITDA is expected to be in the range of $19 – $20 million.
  • Adjusted Net Income is expected to be $11.5 – $12.5 million.
  • Adjusted Net Income Per Diluted Share is expected to be $0.06 – $0.08 per share on approximately 155.6 million weighted-average shares outstanding.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-3.2%

Avg return

Earnings day

-5.7%

Avg return

5 days after

-5.8%

Avg return

30 days after

39%

7 / 18 earnings

Positive

+31.7%

Q1 2025

Best reaction

-34.3%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.2%-2.0%-5.2%
Q4 2025-8.6%-12.9%-25.0%
Q3 2025+11.9%+2.6%-6.4%
Q1 2025+31.7%+21.4%+33.1%
Q4 2024-34.3%-43.7%-40.2%
Q3 2024-1.4%+6.3%+8.4%
Q2 2024-1.4%+5.1%+21.6%
Q1 2024-27.1%-27.5%-22.9%
Q4 2023+2.3%-4.2%-13.3%
Q3 2023+27.5%+29.5%+49.5%
Q2 2023-4.0%-6.2%-21.2%
Q1 2023+0.9%-3.7%+7.9%
Q4 2022+3.5%-1.6%-11.5%
Q3 2022-25.0%-29.7%-14.5%
Q2 2022-16.3%-18.6%-35.7%
Q1 2022-17.5%-31.3%-19.4%
Q4 2021+7.6%+13.6%+14.0%
Q3 2021-5.8%+0.2%-23.3%
Q2 2021
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro